Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1997;96:1964-1969

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bjarnason, N. H.
Right arrow Articles by Christiansen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bjarnason, N. H.
Right arrow Articles by Christiansen, C.

(Circulation. 1997;96:1964-1969.)
© 1997 American Heart Association, Inc.


Articles

Raloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed Rabbits

Nina Hannover Bjarnason, MD; Jens Haarbo, MD, PhD; Inger Byrjalsen, MS; Raymond F. Kauffman, PhD; ; Claus Christiansen, MD, PhD

From the Center for Clinical and Basic Research, Ballerup, Denmark (N.H.B., J.H., I.B., C.C.), and Eli Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Ind (R.F.K.).

Background The beneficial effect of long-term hormone replacement therapy in terms of a decreased risk of cardiovascular disease is now generally accepted. Raloxifene, a selective estrogen receptor modulator, has demonstrated hypolipidemic properties while leaving the endometrium unstimulated.

Methods and Results For our study of the effects of raloxifene on atherosclerosis, 75 rabbits were ovariectomized and treated with either raloxifene, 17ß-estradiol, or placebo; 25 rabbits were sham operated and treated with placebo. After 45 weeks, the raloxifene group had two thirds of the aortic atherosclerosis, as evaluated by the cholesterol content of the proximal inner part of the aorta, found in the placebo group (placebo, 577±55.1 nmol/mg protein; raloxifene, 397±53.6 nmol/mg protein; P<.05); the estrogen group had one third of the aortic atherosclerosis in the placebo group (estrogen, 177±32.1 nmol/mg protein; P<.001). The sham-operated group (473±59.6 nmol/mg protein) was not significantly different from placebo. These effects were only partly explained by the changes in serum lipids and lipoproteins, and treatment with both estrogen and raloxifene independently predicted the response in aorta cholesterol. Because plasma levels of total raloxifene were low relative to clinical values in postmenopausal women, dose-response data for raloxifene are required.

Conclusions Our findings indicate that raloxifene hydrochloride has a potentially important antiatherogenic effect, analogous to that observed with estrogen in this model.


Key Words: atherosclerosis • lipids • prevention • estrogen • raloxifene




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
I. Mercier, S. Mader, and A. Calderone
Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism
Cardiovasc Res, October 1, 2003; 59(4): 883 - 892.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Colacurci, D. Manzella, F. Fornaro, M. Carbonella, and G. Paolisso
Endothelial Function and Menopause: Effects of Raloxifene Administration
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2135 - 2140.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. B. Hodgin and N. Maeda
Minireview: Estrogen and Mouse Models of Atherosclerosis
Endocrinology, December 1, 2002; 143(12): 4495 - 4501.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Simoncini, A. R. Genazzani, and J. K. Liao
Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene
Circulation, March 19, 2002; 105(11): 1368 - 1373.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
C. H. Selzman, A. S. Turner, J. S. Gaynor, S. A. Miller, E. Monnet, and A. H. Harken
Inhibition of Intimal Hyperplasia Using the Selective Estrogen Receptor Modulator Raloxifene
Arch Surg, March 1, 2002; 137(3): 333 - 336.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Saitta, D. Altavilla, D. Cucinotta, N. Morabito, N. Frisina, F. Corrado, R. D'Anna, A. Lasco, G. Squadrito, A. Gaudio, et al.
Randomized, Double-Blind, Placebo-Controlled Study on Effects of Raloxifene and Hormone Replacement Therapy on Plasma NO Concentrations, Endothelin-1 Levels, and Endothelium-Dependent Vasodilation in Postmenopausal Women
Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1512 - 1519.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
L. Mosca
The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease
Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. M. Herrington, B. E. Pusser, W. A. Riley, T. Y. Thuren, K. B. Brosnihan, E. A. Brinton, and D. B. MacLean
Cardiovascular Effects of Droloxifene, a New Selective Estrogen Receptor Modulator, in Healthy Postmenopausal Women
Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1606 - 1612.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
F. J. COHEN, S. WATTS, A. SHAH, R. AKERS, and L. PLOUFFE Jr
Uterine Effects of 3-Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60
Obstet. Gynecol., January 1, 2000; 95(1): 104 - 110.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
V. M. Miller
Gender, Estrogen, and NOS : Cautions About Generalizations
Circ. Res., November 26, 1999; 85(11): 979 - 981.
[Full Text] [PDF]


Home page
CirculationHome page
G. A. Figtree, Y.-q. Lu, C. M. Webb, and P. Collins
Raloxifene Acutely Relaxes Rabbit Coronary Arteries In Vitro by an Estrogen Receptor–Dependent and Nitric Oxide–Dependent Mechanism
Circulation, September 7, 1999; 100(10): 1095 - 1101.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
U. Brehme, B. Bruck, N. Gugel, M. Wehrmann, S. Hanke, G. Finking, F. W. Schmahl, and H. Hanke
Aortic Plaque Size and Endometrial Response in Cholesterol-Fed Rabbits Treated With Estrogen Plus Continuous or Sequential Progestin
Arterioscler. Thromb. Vasc. Biol., August 1, 1999; 19(8): 1930 - 1937.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
N. F. Col, S. G. Pauker, R. J. Goldberg, M. H. Eckman, R. K. Orr, E. M. Ross, and J. B. Wong
Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women
Arch Intern Med, July 12, 1999; 159(13): 1458 - 1466.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. E. Mendelsohn and R. H. Karas
The Protective Effects of Estrogen on the Cardiovascular System
N. Engl. J. Med., June 10, 1999; 340(23): 1801 - 1811.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. C. Jordan and M. Morrow
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer
Endocr. Rev., June 1, 1999; 20(3): 253 - 278.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
J. V. Pinkerton and R. Santen
Alternatives to the Use of Estrogen in Postmenopausal Women
Endocr. Rev., June 1, 1999; 20(3): 308 - 320.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
P. Alexandersen, J. Haarbo, I. Byrjalsen, H. Lawaetz, and C. Christiansen
Natural Androgens Inhibit Male Atherosclerosis : A Study in Castrated, Cholesterol-Fed Rabbits
Circ. Res., April 16, 1999; 84(7): 813 - 819.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
W. Khovidhunkit and D. M. Shoback
Clinical Effects of Raloxifene Hydrochloride in Women
Ann Intern Med, March 2, 1999; 130(5): 431 - 439.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Holm, H. L. Andersen, G. Arroe, and S. Stender
Gender Gap in Aortic Cholesterol Accumulation in Cholesterol-Clamped Rabbits : Role of the Endothelium and Mononuclear-Endothelial Cell Interaction
Circulation, December 15, 1998; 98(24): 2731 - 2737.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. U. Bryant, R. F. Kauffman, P. Iversen, D. A. Cox, B. H. Mitlak, and H. Heath III
Comment on Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal Monkeys
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 3001a - 3002.
[Full Text]


Home page
JAMAHome page
B. W. Walsh, L. H. Kuller, R. A. Wild, S. Paul, M. Farmer, J. B. Lawrence, A. S. Shah, and P. W. Anderson
Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
JAMA, May 13, 1998; 279(18): 1445 - 1451.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. D. Delmas, N. H. Bjarnason, B. H. Mitlak, A.-C. Ravoux, A. S. Shah, W. J. Huster, M. Draper, and C. Christiansen
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
N. Engl. J. Med., December 4, 1997; 337(23): 1641 - 1647.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. J. Evans, A. Eckert, K. Lai, S. J. Adelman, and D. C. Harnish
Reciprocal Antagonism Between Estrogen Receptor and NF-{kappa}B Activity In Vivo
Circ. Res., October 26, 2001; 89(9): 823 - 830.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Wassmann, U. Laufs, D. Stamenkovic, W. Linz, J.-P. Stasch, K. Ahlbory, R. Rosen, M. Bohm, and G. Nickenig
Raloxifene Improves Endothelial Dysfunction in Hypertension by Reduced Oxidative Stress and Enhanced Nitric Oxide Production
Circulation, April 30, 2002; 105(17): 2083 - 2091.
[Abstract] [Full Text] [PDF]